Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.

I call it my AI Retirement Playbook. I recommend you check it out now.

Tracey Mccain Biography and Net Worth

EVP of Blueprint Medicines

Tracey is an experienced legal professional with over 20 years of legal, management and transactional experience in the biopharmaceutical industry. Most recently, Tracey served as senior vice president and head of legal for Sanofi Genzyme, a global business unit of Sanofi, as well as a member of Sanofi Genzyme’s executive leadership team and as a member of the leadership team for Sanofi’s global legal department. Prior to that, Tracey served as Genzyme’s general counsel after it was acquired by Sanofi in 2011. In her capacity as Genzyme’s general counsel, Tracey was responsible for all aspects of its legal department in the United States and throughout Europe, including general corporate, commercial and intellectual property matters, and support of business development initiatives. Prior to Genzyme’s acquisition, Tracey was also responsible for managing the securities and employment law teams and support of non-patent litigation. Before Genzyme, Tracey was an associate at the law firm Palmer & Dodge LLP. Tracey received her B.A. in political science from the University of Pennsylvania and her J.D. from Columbia University School of Law.

What is Tracey L. Mccain's net worth?: The estimated net worth of Tracey L. Mccain is at least $5.45 million as of March 7th, 2024. Ms. Mccain owns 60,498 shares of Blueprint Medicines stock worth more than $5,453,290 as of December 21st. This net worth estimate does not reflect any other investments that Ms. Mccain may own. Learn More about Tracey L. Mccain's net worth.
How do I contact Tracey L. Mccain?: The corporate mailing address for Ms. Mccain and other Blueprint Medicines executives is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. Blueprint Medicines can also be reached via phone at (617) 374-7580 and via email at [email protected]. Learn More on Tracey L. Mccain's contact information.
Has Tracey L. Mccain been buying or selling shares of Blueprint Medicines?: Tracey L. Mccain has not been actively trading shares of Blueprint Medicines within the last three months. Most recently, Tracey L. Mccain sold 5,194 shares of the business's stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $90.69, for a transaction totalling $471,043.86. Following the completion of the sale, the executive vice president now directly owns 60,498 shares of the company's stock, valued at $5,486,563.62. Learn More on Tracey L. Mccain's trading history.
Who are Blueprint Medicines' active insiders?: Blueprint Medicines' insider roster includes Jeffrey Albers (CEO), Percy Carter (Insider), George Demetri (Director), Debra Durso-Bumpus (Insider), Mark Goldberg (Director), Kate Haviland (President, CEO & Director), L. Hewes (Insider), Ariel Hurley (Insider), Michael Landsittel (CFO), Philina Lee (Insider), Nicholas Lydon (Director), Tracey Mccain (EVP), Christopher Murray (Insider), Fouad Namouni (Insider), Christina Rossi (Insider), and Charles Rowland, Jr. (Director). Learn More on Blueprint Medicines' active insiders.
Are insiders buying or selling shares of Blueprint Medicines?: In the last twelve months, insiders at the biotechnology company sold shares 29 times. They sold a total of 329,167 shares worth more than $31,791,633.21. The most recent insider tranaction occured on December, 19th when Director Jeffrey W Albers sold 15,000 shares worth more than $1,346,550.00. Insiders at Blueprint Medicines own 4.2% of the company. Learn More about insider trades at Blueprint Medicines.
Information on this page was last updated on 12/19/2024.

Tracey L. Mccain Insider Trading History at Blueprint Medicines

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/7/2024	Sell	5,194	$90.69	$471,043.86	60,498
3/6/2023	Sell	3,322	$45.68	$151,748.96	52,666
12/7/2021	Sell	5,000	$97.30	$486,500.00
11/3/2021	Sell	5,000	$110.56	$552,800.00
9/23/2021	Sell	25,000	$108.85	$2,721,250.00

Tracey L. Mccain Buying and Selling Activity at Blueprint Medicines

Blueprint Medicines Company Overview

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $90.14

$87.99

$90.99

50 Day Range

MA: $92.45

$82.47

$101.39

2 Week Range

Now: $90.14

$72.24

$121.90

Volume

1,267,436 shs

Average Volume

690,807 shs

Market Capitalization

$5.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.59

Most People Are Dead Wrong.

From Brownstone Research | Ad